<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Triheptanoin" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Triheptanoin</book-part-id>
      <title-group>
        <title>Triheptanoin</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Trifluridine" document-type="chapter">Trifluridine</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Trihexyphenidyl" document-type="chapter">Trihexyphenidyl</related-object>
    </book-part-meta>
    <body>
      <sec id="Triheptanoin.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Triheptanoin.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Triheptanoin is synthetic, medium-chain triglyceride that was developed for nutritional support of patients with long-chain fatty acid oxidation disorders. Triheptanoin is given orally by feeding tube titrated to provide approximately 30% of calories. Triheptanoin therapy has not been associated with elevations in serum aminotransferase or bilirubin levels or to instances of clinically apparent liver injury.</p>
        </sec>
        <sec id="Triheptanoin.Background">
          <title>Background</title>
          <p>Triheptanoin (trye hep&#x02019; ta noyn) is a synthetic, purified medium-chain triglyceride that has three 7-carbon chain length fatty acids that is used as a source of calories and fatty acids for adults and children with long-chain fatty acid oxidation disorders (LC-FAOD). The LC-FAODs are rare autosomal recessive disorders caused by defects in the mitochondrial enzymes that metabolize fatty acids, which results in the inability to break down long-chain fatty acids to produce energy and support protein synthesis. In addition, the undigested long-chain fatty acids accumulate and can be toxic to cells. Patients with LC-FAOD suffer from recurrent bouts of muscle pain, rhabdomyolysis, hypoglycemia, liver disease, and cardiomyopathy. The standard therapy is a rigorous diet avoiding fasting and restricting fat intake along with nutritional supplements of food grade medium-chain triglycerides (MCT), which are typically a mixture of triglycerides with 6, 8, 10 or 12 carbon chain fatty acids. In clinical trials in patients with LD-FAOD, triheptanoin was as effective as standard MCT in reducing the number of major clinical events and hospitalizations. Triheptanoin was approved as a source of calories and fatty acids for adults and children with documented LC-FAOD in 2020. Triheptanoin is available as an oral liquid which is diluted with foods, liquids or formula and administered by feeding tube. The dose is titrated attempting to achieve provision of 30% to 35% of the daily caloric intake. Adverse events include abdominal pain, diarrhea, bloating, nausea, and vomiting as well as feeding tube dysfunction. Rare but potentially severe adverse events include pancreatitis. Management of patients with LC-FAOD requires expertise in nutrition and careful monitoring of diet, caloric and fat intake, and the many complications of the disease.</p>
        </sec>
        <sec id="Triheptanoin.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Serum enzyme elevations during triheptanoin therapy are frequent, mostly reflecting the underlying condition of muscle and hepatic accumulation of toxic fatty acid products and lack of adequate energy production. Elevations in CPK were present in 81%, ALT in 72% and AST in 68% of subjects treated in preregistration studies. The elevations were greater than 5 times the upper limit of normal (ULN) of CPK in 47%, ALT in 24% and AST in 15%. Nevertheless, the changes were not considered due to the triheptanoin or MCT therapy but rather to the underlying metabolic disorder and mitochondrial dysfunction. In small trials of triheptanoin in other genetic metabolic diseases, laboratory values were reported to be unchanged during supplementation. Since its approval and more widescale use, there have been no published cases of clinically apparent liver injury attributed to triheptanoin therapy, although its total clinical experience with its use has been limited.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Triheptanoin.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>Triheptanoin is a pure, pharmaceutical grade, synthetic medium-chain triglyceride with three 7 carbon fatty acid chains. There is no evidence that it causes liver injury but is used in patients who frequently have serum aminotransferase elevations.</p>
        </sec>
        <sec id="Triheptanoin.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The product label for triheptanoin does not recommend monitoring of routine liver tests during therapy. It is prudent to monitor routine liver tests before starting triheptanoin because preexisting abnormalities are frequent, and elevations found during therapy should be compared to pretreatment values.</p>
          <p>Drug Class: Nutritional Supplements</p>
        </sec>
      </sec>
      <sec id="Triheptanoin.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Triheptanoin &#x02013; Dojolvi&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Nutritional Supplements</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Triheptanoin">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Triheptanoin.CHEMICAL_FORMULA_AND_STRUCT">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Triheptanoin.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Triheptanoin.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Triheptanoin.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Triheptanoin.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Triheptanoin.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Triheptanoin.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Triheptanoin</td>
                <td headers="hd_h_Triheptanoin.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135026892">620-67-7</ext-link>
</td>
                <td headers="hd_h_Triheptanoin.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C24-H44-O6</td>
                <td headers="hd_h_Triheptanoin.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135026892" document-id-type="sid" document-type="summary" object-id="135026892" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Triheptanoin.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 10 June 2024</p>
        <p>Abbreviations: LC-FAOD, long-chain fatty acid oxidation disorders; MCT, medium-chain triglycerides; ULN, upper limit of normal range.</p>
        <ref-list id="Triheptanoin.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Triheptanoin.REF.fda.2020">
            <mixed-citation publication-type="journal"><collab>FDA</collab>. <source>Integrated Review.</source>
<year>2020</year>.</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF2">
            <mixed-citation publication-type="web">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213687Orig1s000IntegratedR.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213687Orig1s000IntegratedR.pdf</ext-link>
<annotation><p>
<italic toggle="yes">(FDA website with integrated review of data on triheptanoin safety and efficacy submitted in support of the application for approval as therapy of long-chain fatty acid oxidation disorders (LC-FAOD), mentions laboratory abnormalities found during therapy include elevations in CPK [71%], ALT [72%], and AST [67%] which are greater than 5 times the ULN in 47%, 24%, and 15%, the elevations however, were attributed to the underlying disease not to triheptanoin).</italic>
</p></annotation>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.vockley.2015.53">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Vockley</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Marsden</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>McCracken</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>DeWard</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barone</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kakkis</surname>
<given-names>E</given-names></string-name>. <article-title>Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.</article-title>
<source>Mol Genet Metab.</source>
<year>2015</year>;<volume>116</volume>(<issue>1-2</issue>):<fpage>53</fpage>-<lpage>60</lpage>.<annotation><p><italic toggle="yes">(In a retrospective analysis of 29 patients with LC-FAOD treated with triheptanoin [providing 28% of daily caloric intake] for 78 weeks, the annualized rate of major clinical events [rhabdomyolysis, hypoglycemia, myocardiopathy] decreased by 48% compared to previous therapy with standard MCT [providing 17% of daily caloric intake]; no mention of adverse events).</italic></p></annotation><pub-id pub-id-type="pmid">26116311</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.gillingham.2017.831">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gillingham</surname>
<given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Heitner</surname>
<given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rose</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Goldstein</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>El-Gharbawy</surname>
<given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Deward</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.</article-title>
<source>J Inherit Metab Dis.</source>
<year>2017</year>;<volume>40</volume>:<fpage>831</fpage>-<lpage>843</lpage>.<annotation><p><italic toggle="yes">(Among 32 patients with LC-FAOD treated with either triheptanoin or trioctanoin for 4 months, slight improvements in cardiac function was found with the 7 carbon but not the 8 carbon triglyceride, while adverse events were similar with the two products; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">28871440</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.hainque.2017.160">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hainque</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Caillet</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Leroy</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Flamand-Roze</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Adanyeguh</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Charbonnier-Beaupel</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Retail</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood.</article-title>
<source>Orphanet J Rare Dis.</source>
<year>2017</year>;<volume>12</volume>:<fpage>160</fpage>.<annotation><p><italic toggle="yes">(Among 10 patients with alternating hemiplegia of childhood treated with triheptanoin or placebo in a cross-over design, there were no differences in paroxysmal events between the treatment and placebo periods and adverse event rates were similar [50% vs 70%] and triheptanoin was considered &#x0201c;well tolerated&#x0201d;; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">28969699</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.vockley.2017.370">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Vockley</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Burton</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname>
<given-names>GT</given-names></string-name>, <string-name name-style="western"><surname>Longo</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sanchez-Valle</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tanpaiboon</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24 weeks of treatment.</article-title>
<source>Mol Genet Metab.</source>
<year>2017</year>;<volume>120</volume>:<fpage>370</fpage>-<lpage>377</lpage>.<annotation><p><italic toggle="yes">(Among 29 patients with LC-FAOD treated with triheptanoin for 24 weeks, improvements in exercise tests occurred in most patients tested and adverse events were frequent, most commonly diarrhea, nausea, vomiting and abdominal pain; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">28189603</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.schiffmann.2018.877">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Schiffmann</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wallace</surname>
<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Rinaldi</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ledoux</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Luton</surname>
<given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Coleman</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Akman</surname>
<given-names>HO</given-names></string-name>, <etal>et al.</etal>
<article-title>A double-blind, placebo-controlled trial of triheptanoin in adult polyglucosan body disease and open-label, long-term outcome.</article-title>
<source>J Inherit Metab Dis.</source>
<year>2018</year>;<volume>41</volume>:<fpage>877</fpage>-<lpage>883</lpage>.<annotation><p><italic toggle="yes">(Among 19 patients with adult polyglucosan body disease treated with triheptanoin or vegetable oil for one year, there were no differences in changes in 6-minute walk test or in adverse event rates, most of which were considered unrelated to the therapy; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">29110179</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.merritt.2018.473">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Merritt</surname>
<given-names>JL</given-names>
<suffix>2nd</suffix></string-name>, <string-name name-style="western"><surname>Norris</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kanungo</surname>
<given-names>S</given-names></string-name>. <article-title>Fatty acid oxidation disorders.</article-title>
<source>Ann Transl Med.</source>
<year>2018</year>;<volume>6</volume>:<fpage>473</fpage>.<annotation><p><italic toggle="yes">(Review of fatty acid oxidation disorders, a series of rare [1:5000-1:10,000 births] severe autosomal recessive conditions due to inability to metabolize fatty acids to enter the citric acid cycle for energy production; having variable presentations, neonatally typically with cardiomyopathy, in childhood with hypoglycemia and liver dysfunction [Reyes-like syndrome of acute fatty liver], in adolescence with episodic rhabdomyolysis; treated with avoidance of fasting, a fat-restricted diet, aggressive treatment of intercurrent illnesses, and for LC-FAOD, supplementation with MCT; no discussion of adverse events with therapies).</italic></p></annotation><pub-id pub-id-type="pmid">30740404</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.borges.2019.153">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Borges</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kaul</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Germaine</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kwan</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>O'Brien</surname>
<given-names>TJ</given-names></string-name>. <article-title>Randomized trial of add-on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy.</article-title>
<source>Epilepsia Open.</source>
<year>2019</year>;<volume>4</volume>:<fpage>153</fpage>-<lpage>163</lpage>.<annotation><p><italic toggle="yes">(Among 34 adults with refractory epilepsy treated with titrated triheptanoin or conventional medium-chain triglycerides for 15 weeks, there were no differences in rates or changes in seizure frequency or in rates of adverse events and all blood tests showed no clinically significant changes).</italic></p></annotation><pub-id pub-id-type="pmid">30868125</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.shirley.2020.1595">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shirley</surname>
<given-names>M.</given-names></string-name>
<article-title>Triheptanoin: First Approval.</article-title>
<source>Drugs.</source>
<year>2020</year>;<volume>80</volume>:<fpage>1595</fpage>-<lpage>1600</lpage>.<annotation><p><italic toggle="yes">(Review of the structure, mechanism of action, history of development, clinical efficacy, and safety of triheptanoin shortly after its approval for use in the US, mentions that it is &#x0201c;generally well tolerated&#x0201d; and that most adverse events are mild-to-moderate [diarrhea, abdominal pain, nausea and vomiting], or are due to the underlying condition [fatigue, rhabdomyolysis, myalgia]; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">32897506</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.vockley.2021.253">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Vockley</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Burton</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Longo</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sanchez-Valle</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chapman</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal>
<article-title>Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.</article-title>
<source>J Inherit Metab Dis.</source>
<year>2021</year>;<volume>44</volume>:<fpage>253</fpage>-<lpage>263</lpage>.<annotation><p><italic toggle="yes">(Among 75 patients with LC-FAOD enrolled in a 24-week controlled trial of triheptanoin vs MCT and then into a long term, open label study, the annualized rate of major clinical events [rhabdomyolysis, hypoglycemia, cardiomyopathy] decreased by 45% in those continued on triheptanoin and by 70% of those started de novo on the supplement, and while adverse event rates were high [99%], they were usually unrelated to therapy, and there were &#x0201c;no noteworthy changes in ...chemistry&#x02026; laboratory values&#x0201d;).</italic></p></annotation><pub-id pub-id-type="pmid">32885845</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.striano.2022.1748">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Striano</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Auvin</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Horvath</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Scheffer</surname>
<given-names>IE</given-names></string-name>, <string-name name-style="western"><surname>Tzadok</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname>
<given-names>I</given-names></string-name>, <etal>et al.</etal>
<article-title>A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome.</article-title>
<source>Epilepsia.</source>
<year>2022</year>;<volume>63</volume>:<fpage>1748</fpage>-<lpage>1760</lpage>.<annotation><p><italic toggle="yes">(Among 36 children, adolescents and adults with drug resistant seizures associated with glucose transporter 1 deficiency treated with triheptanoin or placebo for 8 weeks followed by open label triheptanoin for up to one year, there was a 13% reduction in seizures in triheptanoin treated subjects related to baseline and placebo, but adverse events were more frequent including diarrhea, abdominal pain, nausea and vomiting, while there were no treatment related serious adverse events and routine laboratory testing showed no &#x0201c;clinically significant changes&#x0201d;).</italic></p></annotation><pub-id pub-id-type="pmid">35441706</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.lasio.2023.107605">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lasio</surname>
<given-names>MLD</given-names></string-name>, <string-name name-style="western"><surname>Leshinski</surname>
<given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Ducich</surname>
<given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Flore</surname>
<given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Lehman</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shur</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Jayakar</surname>
<given-names>PB</given-names></string-name>, <etal>et al.</etal>
<article-title>Clinical, biochemical and molecular characterization of 12 patients with pyruvate carboxylase deficiency treated with triheptanoin.</article-title>
<source>Mol Genet Metab.</source>
<year>2023</year>;<volume>139</volume>:<elocation-id>107605</elocation-id>.<annotation><p><italic toggle="yes">(Among 12 subjects with pyruvate carboxylase deficiency treated with triheptanoin for variable periods [6 days to 7 years], there was considerable variability in clinical responses [lactate and amino acid levels, quality of life scores] but it was &#x0201c;found to be safe and with no serious adverse events&#x0201d;, although dose adjustments were sometimes needed for gastrointestinal intolerance).</italic></p></annotation><pub-id pub-id-type="pmid">37207470</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.vockley.2023.943">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Vockley</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Burton</surname>
<given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Longo</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sanchez-Valle</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chapman</surname>
<given-names>KA</given-names></string-name>, <etal>et al.</etal>
<article-title>Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study.</article-title>
<source>J Inherit Metab Dis.</source>
<year>2023</year>;<volume>46</volume>:<fpage>943</fpage>-<lpage>955</lpage>.<annotation><p><italic toggle="yes">(In a final report of long term [3-4 years], open label therapy with triheptanoin for LC-FAODs, the overall adverse event rate was 97% and serious adverse event rate 75%, but most adverse events were related to the underlying disease and there were no liver related serious adverse events and no mention of ALT elevations).</italic></p></annotation><pub-id pub-id-type="pmid">37276053</pub-id>
</mixed-citation>
          </ref>
          <ref id="Triheptanoin.REF.de_giorgis.2024">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>De Giorgis</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Bhatia</surname>
<given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Boespflug-Tanguy</surname>
<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Gras</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Marina</surname>
<given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Desurkar</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Toledo</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Triheptanoin did not show benefit versus placebo for the treatment of paroxysmal movement disorders in glut1 deficiency syndrome: results of a randomized phase 3 study.</article-title>
<source>Mov Disord.</source>
<year>2024</year>
<month>May</month>
<day>9</day>. <comment>Epub ahead of print</comment>.<annotation><p><italic toggle="yes">(Among 43 patients with paroxysmal movement disorders due to Glut1 deficiency syndrome treated with triheptanoin or placebo for 10 weeks, there were no differences in rates of disabling movement events or in adverse event rates [93% vs 81%], which were mostly diarrhea, nausea and vomiting and abdominal pain while serious adverse events were uncommon and unrelated; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">38725190</pub-id>
</mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Triheptanoin.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Triheptanoin+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Triheptanoin: from PubMed.gov</ext-link>
</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Triheptanoin">Trials on Triheptanoin: from ClinicalTrials.gov</ext-link>
</p>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
